BiotechTube
E-Star BioTech

E-Star BioTech

San Diego, United States· Est. 2021

E-Star BioTech is a private biotech company focused on advancing a platform of GC-A agonist peptides, with its lead asset MANP in Phase 2 development for resistant hypertension. The company has secured $36 million in grants and seed-stage private investment and holds an exclusive worldwide license from Mayo Clinic for MANP. With a strong scientific foundation and a seasoned leadership team, E-Star aims to bring a new class of therapeutics to the significant unmet need in hypertension and related cardiometabolic disorders.

e-star.bio

Private Company

Funding information not available

AI Company Overview

E-Star BioTech is a private biotech company focused on advancing a platform of GC-A agonist peptides, with its lead asset MANP in Phase 2 development for resistant hypertension. The company has secured $36 million in grants and seed-stage private investment and holds an exclusive worldwide license from Mayo Clinic for MANP. With a strong scientific foundation and a seasoned leadership team, E-Star aims to bring a new class of therapeutics to the significant unmet need in hypertension and related cardiometabolic disorders.

CardiovascularMetabolicRenal

Technology Platform

A platform of engineered Guanylyl Cyclase-A (GC-A) receptor agonist peptides, designed to amplify the body's natural natriuretic peptide system for treating hypertension and related cardiometabolic diseases.

Opportunities

The primary opportunity is addressing the massive, underserved population of patients with uncontrolled and resistant hypertension, estimated at over 1 billion globally.
Success with MANP could also enable expansion into adjacent multi-billion dollar markets like heart failure (HFpEF) and chronic kidney disease, where the drug's mechanism offers potential renoprotective and metabolic benefits.

Risk Factors

Key risks include clinical trial failure in the ongoing Phase 2 study, the challenge of securing future financing as a private company, and the difficulty of achieving commercial differentiation in the crowded hypertension market with a peptide therapy that may require subcutaneous administration.

Competitive Landscape

E-Star competes in the hypertension space against numerous generic and branded drugs. Its main differentiation is targeting the GC-A receptor with a designer peptide, a novel mechanism that aims to replicate and enhance the body's natural blood pressure regulation system. Key competitors include developers of sGC stimulators (e.g., vericiguat for HF) and other novel pathway inhibitors, but MANP's pleiotropic profile (BP lowering, renal protection, metabolic improvement) could carve out a unique niche.